Logo image of SAN.PA

SANOFI (SAN.PA) Stock Price, Forecast & Analysis

Europe - EPA:SAN - FR0000120578 - Common Stock

86.51 EUR
+1.07 (+1.25%)
Last: 11/10/2025, 11:14:16 AM

SAN.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap210.74B
Revenue(TTM)66.91B
Net Income(TTM)13.81B
Shares2.44B
Float2.17B
52 Week High110.88
52 Week Low76.15
Yearly Dividend3.79
Dividend Yield4.58%
EPS(TTM)7.6
PE11.38
Fwd PE10.07
Earnings (Next)01-28 2026-01-28/amc
IPO2002-07-01
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


SAN.PA short term performance overview.The bars show the price performance of SAN.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 -2 4 -4 -6 -8

SAN.PA long term performance overview.The bars show the price performance of SAN.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -2 -4 -6 -8 -10

The current stock price of SAN.PA is 86.51 EUR. In the past month the price increased by 2.52%. In the past year, price decreased by -10.76%.

SANOFI / SAN Daily stock chart

SAN.PA Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
SNW.DE SANOFI11.24208.11B
MRK.DE MERCK KGAA12.9747.98B
UCB.BR UCB SA35.3444.13B
1BAYN.MI BAYER AG-REG5.2826.00B
BAYN.DE BAYER AG-REG5.2825.99B
REC.MI RECORDATI INDUSTRIA CHIMICA25.5810.54B
IPN.PA IPSEN12.3110.59B
TUB.BR FINANCIERE DE TUBIZE98.329.10B
VIRP.PA VIRBAC SA20.272.95B
DMP.DE DERMAPHARM HOLDING SE16.931.81B
MEDCL.PA MEDINCELL SAN/A1.02B
9VC.DE ATAI LIFE SCIENCES NVN/A861.29M

About SAN.PA

Company Profile

SAN logo image Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Company Info

SANOFI

46 Avenue de la Grande Armee

Paris ILE-DE-FRANCE FR

Employees: 82878

SAN Company Website

SAN Investor Relations

Phone: 33153774000

SANOFI / SAN.PA FAQ

Can you describe the business of SANOFI?

Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.


What is the current price of SAN stock?

The current stock price of SAN.PA is 86.51 EUR. The price increased by 1.25% in the last trading session.


Does SAN stock pay dividends?

SANOFI (SAN.PA) has a dividend yield of 4.58%. The yearly dividend amount is currently 3.79.


How is the ChartMill rating for SANOFI?

SAN.PA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


How is the valuation of SANOFI (SAN.PA) based on its PE ratio?

The PE ratio for SANOFI (SAN.PA) is 11.38. This is based on the reported non-GAAP earnings per share of 7.6 and the current share price of 86.51 EUR.


What is the market capitalization of SAN stock?

SANOFI (SAN.PA) has a market capitalization of 210.74B EUR. This makes SAN.PA a Mega Cap stock.


SAN.PA Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to SAN.PA. When comparing the yearly performance of all stocks, SAN.PA is a bad performer in the overall market: 77.47% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SAN.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to SAN.PA. While SAN.PA belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SAN.PA Financial Highlights

Over the last trailing twelve months SAN.PA reported a non-GAAP Earnings per Share(EPS) of 7.6. The EPS decreased by -5.35% compared to the year before.


Industry RankSector Rank
PM (TTM) 20.35%
ROA 11.05%
ROE 19.73%
Debt/Equity 0.21
Chartmill High Growth Momentum
EPS Q2Q%1.75%
Sales Q2Q%-7.47%
EPS 1Y (TTM)-5.35%
Revenue 1Y (TTM)2.56%

SAN.PA Forecast & Estimates

29 analysts have analysed SAN.PA and the average price target is 106.43 EUR. This implies a price increase of 23.02% is expected in the next year compared to the current price of 86.51.

For the next year, analysts expect an EPS growth of 3.07% and a revenue growth 0.53% for SAN.PA


Analysts
Analysts81.38
Price Target106.43 (23.03%)
EPS Next Y3.07%
Revenue Next Year0.53%

SAN.PA Ownership

Ownership
Inst Owners47.5%
Ins Owners0.01%
Short Float %N/A
Short RatioN/A